CMS to make new Alzheimer’s disease drugs available with real-world data collection caveat

The announcement from CMS will ensure innovative new treatments for Alzheimer’s disease will be covered by Medicare on the basis that patients agree to participate in a registry collecting real-world data.  Centers for Medicare & Medicaid Services (CMS) has announced plans to ensure drugs that have been shown to slow the progression of Alzheimer’s disease will be covered by Medicare as soon as they are approved by the FDA. Under the plan, explained by CMS Administrator Chiquita Brooks-LaSure, CMS will provide to patients who meet three specific criteria: a diagnosis of mild cognitive impairment or early dementia caused by Alzheimer’s...